PFSAHealthcare · Medical Devices

PFSA Stock Forecast: Profusa, Inc. Price Predictions for 2026-2027

Last close, 31 July 2026

$1.06

Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 8 of 100 as at 1 Aug 2026 — in the weakest quartile.

Market cap

$561,800.00

Ticker Nerd rank

8 / 100

Median analyst target

—

Analysts covering

—

Ticker Nerd rank

PFSA stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Profusa, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 1 Aug 2026

8 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size

100

Accruals

Revisions

Growth

Volatility

Momentum

Issuance

Value

Quality

Size (100): Smaller than most of the companies we track.

Quality (1): Profits are thin or unreliable for the size of the business, or they are not turning into cash.

The rank is the raw material. Whether the rules would actually own Profusa, Inc. — and when they’d sell — is the membership.

Wall Street

PFSA stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on PFSA, reported as data — targets and ratings, the market's view beside the model's.

We don’t hold enough price history for this company yet.

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Estimates

PFSA analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year

Analysts raising

Analysts cutting

Fundamentals

Profusa, Inc. (PFSA) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation

Trailing P/E: −0.0×
Price / sales: —
Price / book: −0.1×
EV / EBITDA: −0.4×

Growth & margins

Revenue growth (YoY): —
Earnings growth (YoY): —
Gross margin: —
Operating margin: 0.0%
Net margin: 0.0%

Returns & dividend

Return on equity: 134.4%
Return on assets: −923.2%
Dividend yield: —

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

PFSA vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelMedical Devices

Company	Market cap	TKN rank
PFSAProfusa, Inc.	$561,800.00	8
NUWENuwellis, Inc.	$633,900.00	24
BJDXBluejay Diagnostics, Inc.	$889,900.00	21
VTAKCatheter Precision, Inc.	$906,000.00	28
AEMDAethlon Medical, Inc.	$1.7M	23
IVFINVO Fertility, Inc.	$2.1M	47
FEEDENvue Medical, Inc.	$2.9M	25

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. PFSA appears on the weeks it earns a place.

News

Latest PFSA news & analysis

Profusa Announces Signing of Option Agreement for the Acquisition of a Commercial Stage Diagnostics Company, G3 Vision Labs

GlobeNewsWire · 31 July 2026positive

Profusa announced it has signed an Option Agreement granting the right, but not the obligation, to acquire G3 Vision Labs, a commercial stage diagnostics company with estimated 2025 net revenues of approximately $111 million.

Why it matters — The agreement gives Profusa a potential pathway to acquire a revenue-generating diagnostics business, which could expand its commercial footprint beyond biosensing technologies.

Profusa Announces Key Management Changes and Signing of Non-Binding Term Sheet for the Acquisition of a Commercial Stage Diagnostics Company

GlobeNewsWire · 27 July 2026neutral

Profusa announced it has signed a non-binding term sheet to acquire a privately held, commercial-stage health diagnostics and toxicology testing company.

Why it matters — A PFSA watcher would care because this potential acquisition could mark a strategic shift for Profusa from a development-stage biosensing company toward a commercial-stage diagnostics business.

FAQ

Frequently asked questions about PFSA stock

How does Ticker Nerd's model rank PFSA?

As at 1 Aug 2026, Profusa, Inc. ranks 8 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (100 of 100).

What is the PFSA stock forecast for 2030?

No analyst covering Profusa, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for PFSA are extrapolating price history, which says nothing about the business.

What does Profusa, Inc. do?

Profusa, Inc. is a clinical-stage digital health and medical technology company developing biosensing solutions to improve health outcomes for patients with various diseases and conditions.

What is the latest news on PFSA?

The most recent item we track (GlobeNewsWire, 31 July 2026): "Profusa Announces Signing of Option Agreement for the Acquisition of a Commercial Stage Diagnostics Company, G3 Vision Labs". Profusa announced it has signed an Option Agreement granting the right, but not the obligation, to acquire G3 Vision Labs, a commercial stage diagnostics company with estimated 2025 net revenues of approximately $111 million.

Company

About Profusa, Inc.

Profusa, Inc. is a clinical-stage digital health and medical technology company developing biosensing solutions to improve health outcomes for patients with various diseases and conditions. Its innovative technology features bioengineered sensors designed to integrate with the body, enabling continuous detection and transmission of actionable, clinical-grade data for personal and medical applications. A key product, the Lumee Oxygen Platform, available in the European Union, provides reliable long-term monitoring of tissue oxygen levels in targeted body regions. Profusa also engages in biofeedback services supporting chronic disease management and healthy living. Operating within the electronic technology sector, particularly semiconductors for medical applications, the company addresses needs in healthcare monitoring and diagnostics. Headquartered in Berkeley, California, Profusa, Inc. focuses on advancing implantable sensor technologies to deliver real-time physiological insights, playing a role in the growing digital health market by bridging personal wellness and professional medical care.

CEO Dr. Ben Chung-Bin Hwang Ph.D. · United States · https://profusa.com